Kornimate/medical-research-clean huggingface dataset:
learn: learning environment for artificial intelligence in radiotherapy new technology

Conditions: Arrhythmias, Cardiac; Breast Cancer; Prostatic Cancer; Brain Cancer; Kidney Cancer; Head and Neck Cancer; Liver Cancer; Pancreatic Cancer; Spinal Neoplasm

Summary: this study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. when the markerless tracking method is sufficiently advanced, according to the pi of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

this observational study will access routinely acquired radiation therapy treatment data from 300 patients including brain, breast, head and neck, kidney, liver, pancreas, prostate, spine and cardiac anatomic sites. at least 30 patients will be recruited from each anatomic site to enable sufficient data for the markerless tracking method training, testing and validation. the clinical data will be used to develop, train, test and validate a markerless target tracking method. after the treatment, the ground truth and the variability in the ground truth will be computed. the patient images, the markerless tracking results, the ground truth and the variability will be uploaded to an in-house developed clinical trial learning system. uploading additional data to the learning system automatically triggers the model building of the deep learning system. in this manner, the learning system gets both more accurate and more robust with each patient accrued. as the patient data accrues, the primary hypothesis of targeting accuracy can be tested. the developed markerless tracking software will be applied by study personnel to the treatment imaging data for each anatomic site using five-fold cross-validation where 80% of the data is used for training and the remaining unseen 20% of the data is used for testing. target positions produced by the markerless tracking will be compared with a 'ground truth'.

Eligibility criteria:
inclusion criteria: * will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre. * will receive ct planning, and a cone beam ct scan for at least one fraction of radiation therapy. * will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. as intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites. * provides written informed consent. exclusion criteria: * less than 18 years of age

Keywords: radiation therapy markerless tracking
impact of prolonged cold-water swimming on heart rate and cardiac function

Conditions: Hypothermia

Summary: a significant medical risk associated with hypothermia during exercise in a cold environment cardiac arrhythmia due to a possible autonomic conflict. however, little is known about the changes in heart rate and cardiac function after prolonged cold water swimming. the investigators propose to measure the changes in core temperarure during and after a cold water swim at at a water temperature below 15.5°c qualifying for english channel swim and to test the association with changes in heart rate variability, resting electrocardiogram and left ventricle function.


Eligibility criteria:
inclusion criteria: * swimmers taking part in the channel swim camp * swimmers above 18 years of age * swimmers willing and able to give informed consent for participation in the study exclusion criteria: * swallowing disorder * chronic gastrointestinal disease * mri scheduled within 48 hours after the race. * known cardiac arythmia or cardiovascular disease
diagnosis of heart failure in chronic obstructive pulmonary disease using the lung ultrasound

Conditions: Dyspnea; Decompensated Heart Failure ; COPD Exacerbation

Summary: acute heart failure (ahf) is a common cause of acute exacerbation of chronic obstructive pulmonary disease (aecopd). this association is frequently underestimated with regard to the difficulty of clinical diagnosis. the investigators expect that the application of the lung ultrasound could be useful in this issue.

chronic obstructive pulmonary disease (copd) is a frequent disease in our population affecting mainly the elderly and males. dyspnea is the most common reason for consultation for patients with copd in ed. distinguishing between pulmonary and/or cardiac origin can be challenging.physical examination, laboratory findings and radiography are imperfect. lung ultrasound sonography (lus) has recently gained a large place in the diagnosis of heart failure (hf), but its contribution to the diagnosis of hf in copd remains poorly studied. purpose: the purpose of this study is to assess the contribution of lus in the diagnosis of hf in copd patients with acute dyspnea . physical examination, laboratory findings and radiography are imperfect, resulting in a need for sophisticated test results that delay management. lung ultrasonography is becoming a standard tool in critical cases in the ed. the investigators aim to perform ultrasonography on copd patients admitted to the icu with dyspnea, comparing lung ultrasonography results on initial presentation with the final diagnosis by the icu team. three items were assessed: artifacts (horizontal a lines or vertical b lines indicating interstitial syndrome), lung sliding, and alveolar consolidation and/or pleural effusion, these items were grouped to assess ultrasound profiles. this study assesses the potential of lung ultrasonography to diagnose heart failure.the second aim of this study was to evaluate the inter-observer reproducibility of lus performed by ed residents in the evaluation of cardiac causes of acute dyspnea.this study includes patients with copd consulting for acute dyspnea. we performed a lung ultrasound on all patients included. the diagnosis of heart failure (hf) was based on clinical, radiological, cardiac-ultrasound and expert data. the lus diagnostic performance indicators were calculated using the different cut-off proposed by the lus score.then the probability of ahf was defined as : low probability (lus\<15) intermediate probability (15≤ lus\<30), and high probability (lus≥30 ).

Eligibility criteria:
inclusion criteria: * patients with history of copd admitted to the emergency department for dyspnea non traumatic dyspnea exclusion criteria: * instable hemodynamic or neurological status non consent to participate in the study

Keywords: copd acute heart failure lung ultrasound
increase surveillance for breast and ovarian cancers, also to determine targeted risk-reducing and preventative strategies

Conditions: Hereditary Cancer

Summary: observational study is to increase surveillance for breast and ovarian cancers, also to determine targeted risk-reducing and preventative strategies.

the general design of this study is collecting data and reviewing the principal investigators' (p.i.) standard operating procedures (sop) on brca testing and changes made to their specific sop.

Eligibility criteria:
inclusion criteria: * must be a medical practitioner * medical doctor (md) * doctor of osteopathic (do) * physician assistant (pa) * advanced practice registered nurse (aprn) * nurse practitioner (np) * must have a current standard operating procedure that includes obtaining/reviewing medical history and family medical history exclusion criteria: * government-funded insurance data cannot be included in the study.
pillsense use in anemia and hemoccult

Conditions: Occult Gastrointestinal Bleeding; Upper Gastrointestinal Bleeding (UGIB)

Summary: in this study, participants will be offered a pillsense™ capsule, a small capsule to swallow, which can detect the presence of blood in the upper digestive tract within about 10 minutes. the results of this capsule test will not alter the current care plan but will help us assess whether pillsense™ can be used in the future as a standalone test to determine if it is safe for patients to be discharged with anemia or a positive stool test without other signs of gastrointestinal bleeding. this study aims to collect data that will help determine if the pillsense™ capsule could one day reduce the need for more invasive procedures while hospitalized, like endoscopy, and ensure safe patient discharge.


Eligibility criteria:
inclusion criteria: * age 18 years or older * able to provide informed consent * hospitalized patients who have been referred to the gastroenterology service for: a positive hemoccult (fecal occult blood test) and/or anemia, in the absence of overt gastrointestinal bleeding - overt gastrointestinal bleeding is defined as the presence of: melena (black, tarry stools) hematochezia (bright red blood per rectum) hematemesis (vomiting blood) exclusion criteria: * hemodynamic instability, defined as: systolic blood pressure \ 120 bpm * presence of overt gastrointestinal bleeding (melena, hematochezia, or hematemesis) * conditions that might contraindicate use of an ingestible capsule, such as: dysphagia or odynophagia swallowing disorder altered mental status zenker's diverticulum crohn's disease previous gi surgery suspected ileus or bowel obstruction gi perforation gi motility disorders (e.g., esophageal dysmotility, gastroparesis) - known upper gi pathology, such as: esophageal or gastric cancer recent upper gi ulcer bleeding (within 3 months) recent upper gi procedures or surgeries * presence of a cardiac implantable electronic device (cied) * pregnant or lactating women * planned mri before capsule excretion

Keywords: pillsense upper gastrointestinal bleeding gi bleed detection positive hemoccult capsule endoscopy non-invasive diagnostics real-time gi bleed detection
the effect of spray on propofol injection pain

Conditions: Pain

Summary: while propofol is widely used an anesthetic induction medication, it causes the mild to moderate pain. investigators will investigate the effect of ethyl chloride spray on propofol injection pain.


Eligibility criteria:
inclusion criteria: * the female patients undergoing hysteroscopy exclusion criteria: * the patients who are pregnant, have raynaud's syndrome, or receive the pain killer
safety and efficacy of botulinum toxin a in patients with trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: this is a double-blind randomized clinical trial comparing the pain reduction of individuals treated with btx-a and placebo as well as evaluating possible changes in neuroinflammatory biomarkers. the trial lasts 16 weeks, with a 4-week baseline phase and a 12-week randomization phase. four visits are planned: 1) introduction and baseline data collection, 2) medical evaluation and treatment assignment, 3) follow-up with biomarker analysis, and 4) trial conclusion interview. 80 participants will be included and randomized 1:1.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of classical tn or idiopathic tn according to criteria of the international classification of headache disorders 3rd edition. 2. age between 18 and 85 years. 3. subjects must experience pain defined as a minimum of three tn related pain paroxysms per day at least four days a week of an average intensity of 4 to 10, inclusive, on the 11-point nrs (0 = no pain; 10 = maximum pain imaginable) during the last 4 weeks to enter the baseline phase. 4. during baseline phase subjects must experience pain defined as a minimum of three tn related pain paroxysms per day at least four days a week of an intensity of an average 4 to 10, inclusive, on the 11-point nrs (0= no pain; 10= maximum pain imaginable) during the last month to enter the treatment phase (to be randomized). 5. fluency in danish. exclusion criteria: 1. severe cardiovascular and cerebrovascular disease such as ischemic heart disease, myocardial infarction or previous stroke or transient ischemic attack, major cvd interventions during the last three months. 2. expected poor compliance, i.e., considered unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge. 3. ongoing and unstable severe psychiatric disease. 4. anamnestic or clinical symptoms of any kind that are deemed relevant for study participation by the physician who examines the patient. 5. change of tn treatment or treatment dose within two weeks prior to the baseline visit. 6. previous treatment with btx-a for facial pain. 7. loading treatment within 4 weeks with phenytoin or sodium valproate. 8. female subjects either pregnant, breastfeeding or with planned conception within the study period. 9. female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during the study. 10. known allergy to any component of btx-a. 11. infection at the proposed injection site. 12. known severe neuromuscular disorders or any degree of disorder affecting the neuromuscular transmission. 13. known comprised respiratory function. 14. member of investigational site staff or relative of the investigator.
eicosapentaenoic acid (epa)and docosahexaenoic acid study

Conditions: Heart Disease

Summary: the goal of the study is to test the efficacy of an epa-enriched oil made by dupont versus a dha-enriched oil, a standard fish oil preparation, and olive oil placebo in a double-blind, randomized, placebo-controlled trial. this study will compare the efficacy of 1800 mg/day of epa versus 1800 mg/day of dha versus a fish oil product containing 1800 mg of epa and 1200 mg of dha/day as compared to olive oil placebo at 6 grams/day over a 6 week period in a parallel arm design study of 120 healthy adults studied in both the fasting and post-prandial state. safety will be monitored by assessing for adverse reactions, measuring vital signs and a variety of lab tests including a complete metabolic profile and complete blood count. efficacy will be assessed by measuring changes in fatty acid profile and or fatty acid ratios,as well as by measuring plasma lipids, lipoproteins, and markers of inflammation.


Eligibility criteria:
inclusion criteria: * healthy male or surgically sterile females between ages 21-70. * body mass index of 20-35. * plasma lipoprotein associated phospholipase a2 (lppla2) values \> 200 ng/ml. exclusion criteria: * competitive exerciser. * current smoker. * those already taking dietary supplements (epa, dha, flax seed oil, fish oil, cod liver oil, weight control products, or high doses of vitamin c (\>500 mg/day) or vitamin e (\>400 mg/day). * those consuming more than 3 oily fish species/week. * those consuming \>2 drinks containing alcohol/day. * those taking medications which could affect serum lipids or body weight, or taking coumadin or more than 325 mg/day of aspirin which could effect bleeding time or the coagulation profile. * history of a bleeding disorder. * history of significant cardiac, renal, hepatic, gastro-intestinal, pulmonary, neoplastic, biliary or endocrine disorders including uncontrolled diabetes, thyroid disease, or hypertension. * plasma lppla2 values \< 200 ng/ml.
topical agent for treatment of red skin

Conditions: Rosacea; Bilaterally Symmetric Red Skin on Cheeks

Summary: sr-01 may reduce facial redness. it is a topically applied product. the agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety


Eligibility criteria:
bilaterally symmetric red skin on cheeks caucasian age 18-60 years
evaluate long-term safety and efficacy of oradur®-methylphenidate in children and adolescents with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to evaluate the long-term safety and efficacy of oradur®-methylphenidate in children and adolescents with adhd.

in order to evaluate the long-term safety and efficacy of oradur®-methylphenidate in children and adolescents with adhd, subjects who participated in the previous op-2pn012-301 study will be invited to join this extension study for 24-month follow-up. subjects will continue to receive oradur®-methylphenidate at the previously determined optimal dose.

Eligibility criteria:
main inclusion criteria: 1. subjects previously enrolled in op-2pn012-301 study and completed 4-week study treatment 2. both subjects and parents/guardians have provided their signed and dated informed consent form for the study main exclusion criteria: 1. subjects who experienced unmanageable adverse events (aes) after receiving oradur®-methylphenidate 2. subjects are taking a concomitant medication (ex: monoamine oxidase inhibitor (maoi) or other adhd treatments) that is likely to interfere with safe administration of methylphenidate within 14 day prior to the study treatment initiation 3. subjects are joining other clinical studies and receiving any other investigational medical products within 14 days prior to the study treatment initiation. 4. by the investigators' discretion, subjects with serious or unstable medical illness that will interfere with the evaluations of study efficacy and safety 5. by the investigators' discretion, subjects cannot understand or follow the instructions given in the study 6. psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Keywords: oradur®-methylphenidate
clinical application of non-invasive assessment for staging liver steatosis and liver fibrosis

Conditions: Nonalcoholic Fatty Liver Disease; Liver Steatosis; Liver Fibrosis

Summary: nowadays, the morbidity of nonalcoholic fatty liver disease (nafld) show ascending trend year by year, which has become an important public health problem in china. as nafld can progress to non-alcoholic steatohepatitis (nash), cirrhosis and hepatocarcinoma, the identification and quantitative evaluation of liver steatosis and its dynamic changes are crucial. while liver biopsy is still the gold standard in the diagnosis of nafld, its application is limited because of the invasive procedure.the transient elastography(te) combined with the controlled attenuation parameter(cap) is a new non-invasive diagnostic method for fatty liver and liver fibrosis. in order to evaluate the diagnostic value of non-invasive assessment for the degree of liver steatosis and staging liver fibrosis, this non-invasive method will be assessed by the golden standard of liver biopsy among 400 nafld patients.the treatment protocols will be decided by doctor and patient both (treatment protocols and medicine are not required). blood routine, blood biochemistry, abdominal ultrasound and transient elastography(te) combined with the controlled attenuation parameter(cap) are detected during the follow-up.


Eligibility criteria:
inclusion criteria: * age:18≤,≥65 * gender:male or female * nafld patient,agree with the paracentesis of liver tissue * regular follow-up * signing the informed consent form exclusion criteria: * hepatic decompensation：including cirrhotic complications,such as ascites,hepatic encephalopathy,digestive tract bleeding,hepatorenal syndrome,spontaneous bacterial peritonitis,and hcc. * complications of hbv,hcv,hiv.complications of alcoholic liver disease,autoimmune liver disease,hereditary metabolic liver disease, drug-induced liver disease and other chronic liver disease. * afp\>100ng/ml and imaging indicates malignant occupying.or afp still\>100ng/ml within 3 months. * creatinine was 1.5 times higher than the upper limit of the normal value. * combined with other malignant tumors(except those cured). * serious diseases of heart, lung, kidney, brain, blood and other important organs with dysfunction. * severe neurological and psychiatric diseases (such as epilepsy, depression, mania, schizophrenia, etc.) * pregnant women and breast-feeding women. * the researchers consider that it is not suitable for the patients to participate in this study.

Keywords: non-invasive assessment transient elastography controlled attenuation parameter
evaluation of nutritional habits of university students

Conditions: Eating Habit; Health Knowledge, Attitudes, Practice

Summary: this cross- sectional, single-center study was conducted with the participation of 912 students studying at \[removed for blind peer review\] faculty of health sciences, faculty of engineering and natural sciences, faculty of educational sciences, faculty of social sciences, faculty of law and medicine. the sample size was calculated to be a minimum of 379 with 95% confidence over the total number of students, 5301. the study was carried out between october 2020 and december 2020. the compliance of the study with the ethical rules was evaluated by the istanbul medeniyet university social and human sciences research and publication ethics committee at its meeting dated 27.10.2020 and approved with the decision numbered 2020/39. at the beginning of the study, verbal and written consent was obtained from the individuals and a questionnaire containing 29 questions was distributed by the researchers. the questionnaire form consists of three parts. the first part includes 10 questions to determine the demographic characteristics of the participants, the second part includes 17 questions to determine their eating habits, and the third part includes 2 questions to evaluate the status of following the news about nutrition and heart health and whether they find the public service ads on this subject sufficient.


Eligibility criteria:
inclusion criteria: * volunteering to participate in the research * istanbul medeniyet university students between the ages of 18-25 exclusion criteria: * individuals who did not volunteer to participate in the study * adults over 25 * all university students studying outside of istanbul medeniyet university * elderly individuals * children under 18
methodology study of retroviral insertion site analysis in strimvelis gene therapy

Conditions: Severe Combined Immunodeficiency Due to ADA Deficiency

Summary: this study is a post approval commitment to evaluate the accuracy and precision of retroviral insertion site (ris) analysis and its utility for investigating and predicting the potential for insertional oncogenesis in subjects treated with strimvelis.

this non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with strimvelis. the study does not require subjects to undergo any further treatment, intervention or blood withdrawal. the objective of this methodology study is to evaluate the accuracy and precision of shearing extension primer tag selection ligation-mediated polymerase chain reaction (s-epts/lm-pcr) for ris analysis and its utility for investigating and predicting the potential for insertional oncogenesis in subjects previously treated with strimvelis for severe combined immunodeficiency (scid) due to adenosine deaminase (ada) deficiency.

Eligibility criteria:
inclusion criteria subjects must have previously received treatment with grv-gt, either during clinical development (clinical trials and early access programs) or in the post-marketing setting as the approved product (strimvelis) or under hospital exemption, and for whom at least one biological sample is available that meets the following eligibility criteria:: 1. peripheral blood, bone marrow, or dna extracted from either source. 2. taken at least 6 months after grv-gt. 3. stored at -20oc or below since the time of sampling. 4. likely to provide at least 1.5 μg of dna (following extraction by the central laboratory). exclusion criteria n/a

Keywords: ada-scid retroviral vector gene therapy